Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 184

Similar articles for PubMed (Select 22431917)

1.

Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.

Wong HK, Shimizu A, Kirkpatrick ND, Garkavtsev I, Chan AW, di Tomaso E, Klagsbrun M, Jain RK.

Neoplasia. 2012 Feb;14(2):84-94.

2.

The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.

Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO.

Glia. 2012 Nov;60(11):1721-33. doi: 10.1002/glia.22391. Epub 2012 Jul 20.

PMID:
22821509
3.
4.

Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.

Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E.

Cancer Res. 2010 May 1;70(9):3483-93. doi: 10.1158/0008-5472.CAN-09-3107. Epub 2010 Apr 20.

5.

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V.

Mol Cell Biol. 2009 Aug;29(15):4250-61. doi: 10.1128/MCB.01581-08. Epub 2009 May 18.

6.

Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis.

Schulze KM, Hanemann CO, Müller HW, Hanenberg H.

Hum Mol Genet. 2002 Jan 1;11(1):69-76.

7.

Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.

Yang C, Asthagiri AR, Iyer RR, Lu J, Xu DS, Ksendzovsky A, Brady RO, Zhuang Z, Lonser RR.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4980-5. doi: 10.1073/pnas.1102198108. Epub 2011 Mar 7.

8.

Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein.

Lee H, Kim D, Dan HC, Wu EL, Gritsko TM, Cao C, Nicosia SV, Golemis EA, Liu W, Coppola D, Brem SS, Testa JR, Cheng JQ.

Mol Cell Biol. 2007 Mar;27(6):2103-19. Epub 2007 Jan 8.

9.

Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells.

Flaiz C, Utermark T, Parkinson DB, Poetsch A, Hanemann CO.

Glia. 2008 Apr;56(5):506-15. doi: 10.1002/glia.20629.

PMID:
18240308
10.

Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas.

Kimura Y, Saya H, Nakao M.

Neuropathology. 2000 Sep;20(3):153-60. Review.

PMID:
11132929
11.

Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21.3, in p53-regulated tumor angiogenesis suppression.

Futamura M, Kamino H, Miyamoto Y, Kitamura N, Nakamura Y, Ohnishi S, Masuda Y, Arakawa H.

Cancer Res. 2007 Feb 15;67(4):1451-60.

12.

Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma.

Flaiz C, Ammoun S, Biebl A, Hanemann CO.

Brain Pathol. 2009 Jan;19(1):27-38. doi: 10.1111/j.1750-3639.2008.00165.x. Epub 2008 Apr 25.

PMID:
18445079
13.

The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A.

Neoplasia. 2008 Nov;10(11):1204-12.

14.

Functional analysis of neurofibromatosis 2 (NF2) missense mutations.

Gutmann DH, Hirbe AC, Haipek CA.

Hum Mol Genet. 2001 Jul 1;10(14):1519-29.

15.

Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.

James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, Gusella JF, Stemmer-Rachamimov AO, Ramesh V.

Mol Cancer Res. 2012 May;10(5):649-59. doi: 10.1158/1541-7786.MCR-11-0425-T. Epub 2012 Mar 16.

16.

Universal absence of merlin, but not other ERM family members, in schwannomas.

Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, Burwick JA, Pinney D, Beauchamp R, Jacoby LB, Gusella JF, Ramesh V, Louis DN.

Am J Pathol. 1997 Dec;151(6):1649-54.

17.

Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways.

Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R.

Mol Cancer Ther. 2011 Nov;10(11):2094-103. doi: 10.1158/1535-7163.MCT-11-0243. Epub 2011 Sep 8.

18.

VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation.

Huang J, Chen J.

Oncogene. 2008 Jul 3;27(29):4056-64. doi: 10.1038/onc.2008.44. Epub 2008 Mar 10.

PMID:
18332868
19.
20.

Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.

Lepont P, Stickney JT, Foster LA, Meng JJ, Hennigan RF, Ip W.

Mutat Res. 2008 Jan 1;637(1-2):142-51. Epub 2007 Aug 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk